Moving the Needle: Collaborative Strategies to Overcome Barriers to Insulin Initiation and Adherence
SPONSORSHIP & SUPPORT
This educational activity is jointly provided by the Postgraduate Institute for Medicine and Spire Learning.
This activity is supported by an educational grant from Eli Lilly and Company.
Successful initiation of insulin in a person with diabetes and continual adherence require a combination of clinical knowledge, education and counseling skills, coordination among a large care team, an engaged patient, and processes aligned with optimizing outcomes. Health care professionals will benefit from obtaining clinical insights from experts and from having opportunities to build mentoring and collaborative relationships with other clinicians providing care to patients with diabetes. The goal of this activity is to improve the insulin initiation experience and adherence to insulin in patients with diabetes.
Endocrinologists, primary care physicians, nurse practitioners, physician assistants, certified diabetes educators, pharmacists
ACCREDITATION STATEMENT AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Spire Learning. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: Postgraduate Institute for Medicine designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists: Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-20-2097-H01-P)
Nurse Practitioners/Nurses: The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Type of Activity: Internet-based activity
Hardware/software requirements: Internet connectivity
INSTRUCTIONS ON HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. In order to receive CME/CE credit, you must complete:
• Baseline assessment
• Modules 1, 2, and 3
• Final assessment
• Activity evaluation
Your certificate can be printed immediately.
CONFLICT OF INTEREST STATEMENT
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Irl B. Hirsch, MD
Professor of Medicine
Diabetes Treatment and Teaching Chair
University of Washington
Diabetes Care Center
University of Washington Medical Center
Consulting Fees: Abbott Laboratories; Bigfoot Biomedical, Inc
Contracted Research: Insulet Corp; Medtronic PLC
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Division of Endocrinology, Diabetes, and Bone Disorders
Henry Ford Health System
Advisory Board: Abbott Laboratories; Boehringer Ingelheim/Lilly; Dexcom, Inc; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; Pendulum Therapeutics; Sanofi-Aventis
Speakers Bureau: Abbott Laboratories; AstraZeneca; Boehringer Ingelheim/Lilly; Dexcom, Inc; Eli Lilly and Company; Insulet Corp; Janssen Pharmaceuticals, Inc; Novo Nordisk; Valeritas
Grant/Research Support: Abbott Laboratories; Dexcom, Inc; Helmsley Foundation; Lexicon Pharmaceuticals Inc; Novo Nordisk
Stock: Pendulum Therapeutics
Curtis L. Triplitt, PharmD, CDCES, FADCES
Clinical Associate Professor of Medicine
Division of Diabetes
University of Texas Health Science Center at San Antonio
Texas Diabetes Institute
University Health System
San Antonio, TX
Advisory Board: Xeris Pharmaceuticals, Inc
Speakers Bureau: AstraZeneca; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Novo Nordisk
EDUCATIONAL PLANNING COMMITTEE
Postgraduate Institute for Medicine
Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Amanda Glazar, PhD, CHCP: No relevant financial relationships with any commercial interests.
Ashton Beggs, PharmD, BCACP; Allison Goldberg, MPA; and Lisa Colombo: No relevant financial relationships with any commercial interests.
Patient Planners: No relevant financial relationships with any commercial interests.
This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.
The opinions expressed in this educational activity are those of the faculty and do not represent those of the Postgraduate Institute for Medicine (PIM) or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
Copyright © 2020 by Spire Learning, LLC, and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC, and Postgraduate Institute for Medicine (PIM) will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.